Selected article for: "activating effect and low molecular weight"
Author: Petito, E; Falcinelli, E; Paliani, U; Cesari, E; Vaudo, G; Sebastiano, M; Cerotto, V; Guglielmini, G; Gori, F; Malvestiti, M; Becattini, C; Paciullo, F; De Robertis, E; Bury, L; Lazzarini, T; Gresele, P
Title: Neutrophil more than platelet activation associates with thrombotic complications in COVID-19 patients
  • Cord-id: mr3fyqgr
  • Document date: 2020_12_6
    • ID: mr3fyqgr
    Snippet: BACKGROUND: SARS-CoV-2 infection is associated with hypercoagulability which predisposes to venous thromboembolism (VTE). We analyzed platelet and neutrophil activation in COVID-19 patients and their association with VTE. METHODS: Hospitalized COVID-19 patients and age- and sex-matched healthy controls were studied. Platelet and leukocyte activation, neutrophil extracellular traps (NETs), and matrix metalloproteinase-9 (MMP-9), a neutrophil-released enzyme, were measured. Four patients were re-s
    Document: BACKGROUND: SARS-CoV-2 infection is associated with hypercoagulability which predisposes to venous thromboembolism (VTE). We analyzed platelet and neutrophil activation in COVID-19 patients and their association with VTE. METHODS: Hospitalized COVID-19 patients and age- and sex-matched healthy controls were studied. Platelet and leukocyte activation, neutrophil extracellular traps (NETs), and matrix metalloproteinase-9 (MMP-9), a neutrophil-released enzyme, were measured. Four patients were re-studied after recovery. The activating effect of COVID-19 plasma on control platelets and leukocytes and the inhibiting activity of common antithrombotic agents on it were studied. RESULTS: 36 COVID-19 patients and 31 healthy controls were studied; 8/36 COVID-19 patients (22.2%) developed VTE. Platelets and neutrophils were activated in COVID-19 patients. NET, but not platelet activation, biomarkers correlated with disease severity and were associated with thrombosis. Plasmatic MMP-9 was significantly increased in COVID-19 patients. Platelet and neutrophil activation markers, but less so NETs, normalized after recovery. In vitro, plasma from COVID-19 patients triggered platelet and neutrophil activation and NET formation, the latter blocked by therapeutic dose low-molecular weight heparin, but not by aspirin or dypiridamole. CONCLUSIONS: Platelet and neutrophil activation are key features of COVID-19 patients. NET biomarkers may help to predict clinical worsening and VTE, and may guide LMWH-treatment intensity.

    Search related documents:
    Co phrase search for related documents
    • abnormal coagulation and active site: 1
    • abnormal coagulation and acute coronary syndrome: 1
    • abnormal coagulation and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • abnormal coagulation and lmwh prophylaxis: 1
    • abnormal coagulation and lung damage: 1
    • abnormal coagulation and lung injury: 1, 2, 3, 4, 5
    • activate neutrophil and acute respiratory syndrome: 1, 2
    • activate neutrophil and lung injury: 1
    • activated neutrophil and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • activated neutrophil and lung damage: 1
    • activated neutrophil and lung injury: 1, 2, 3, 4, 5, 6, 7, 8
    • activation marker and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • activation marker and lung damage: 1
    • activation marker and lung injury: 1
    • activation matrix and acute respiratory syndrome: 1, 2
    • activation matrix and lung injury: 1, 2, 3, 4, 5, 6
    • active infection and acute coronary syndrome: 1
    • active infection and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • active infection and lung damage: 1, 2, 3, 4, 5, 6